William Blair analyst Matt Phipps has reiterated their bullish stance on DVAX stock, giving a Buy rating today.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Matt Phipps has given his Buy rating due to a combination of factors including Dynavax’s promising growth trajectory and strategic initiatives. The company has reported its 2024 financial results, showcasing continued market share gains for its Heplisav product, and provided guidance for 2025 that aligns closely with market expectations.
Dynavax’s plans for 2025 involve expanding Heplisav’s access to Medicare patients and integrating hepatitis vaccinations into HEDIS measures, which are expected to support the product’s accelerated growth. Moreover, the company’s management has projected a significant market opportunity for adult hepatitis B vaccines by 2030, with Heplisav capturing a substantial share. These factors, combined with a strong cash position and a favorable valuation, underpin the Buy rating for Dynavax’s stock.
In another report released today, JMP Securities also reiterated a Buy rating on the stock with a $33.00 price target.